A detailed history of Victory Capital Management Inc transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 95,240 shares of ITOS stock, worth $805,730. This represents 0.0% of its overall portfolio holdings.

Number of Shares
95,240
Previous 110,389 13.72%
Holding current value
$805,730
Previous $1.64 Million 40.66%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$10.09 - $17.97 $152,853 - $272,227
-15,149 Reduced 13.72%
95,240 $972,000
Q2 2024

Aug 05, 2024

BUY
$10.33 - $18.09 $171,777 - $300,818
16,629 Added 17.74%
110,389 $1.64 Million
Q1 2024

May 03, 2024

BUY
$9.89 - $13.64 $138,133 - $190,509
13,967 Added 17.5%
93,760 $1.28 Million
Q4 2023

Feb 05, 2024

SELL
$8.57 - $11.06 $165,743 - $213,900
-19,340 Reduced 19.51%
79,793 $873,000
Q3 2023

Nov 06, 2023

BUY
$10.95 - $14.6 $3,843 - $5,124
351 Added 0.36%
99,133 $1.09 Million
Q2 2023

Jul 27, 2023

BUY
$12.93 - $18.05 $185,325 - $258,710
14,333 Added 16.97%
98,782 $1.31 Million
Q1 2023

May 02, 2023

BUY
$13.02 - $22.62 $271,558 - $471,785
20,857 Added 32.8%
84,449 $1.15 Million
Q4 2022

Feb 10, 2023

BUY
$17.77 - $21.6 $61,750 - $75,060
3,475 Added 5.78%
63,592 $1.24 Million
Q4 2022

Feb 09, 2023

BUY
$17.77 - $21.6 $2,860 - $3,477
161 Added 0.27%
60,117 $1.17 Million
Q3 2022

Nov 02, 2022

BUY
$18.6 - $27.25 $90,117 - $132,026
4,845 Added 8.79%
59,956 $1.14 Million
Q2 2022

Aug 01, 2022

BUY
$16.57 - $35.1 $175,492 - $371,744
10,591 Added 23.79%
55,111 $1.14 Million
Q1 2022

May 04, 2022

BUY
$31.92 - $47.45 $1.42 Million - $2.11 Million
44,520 New
44,520 $1.2 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $301M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.